Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KAT7 | O95251 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295644 | 0.86 | TAAR1 (0.45) | KDM4E | |
| SCHEMBL6292665 | 0.84 | KDM4E (0.50) | RAB9AKDM4EMAPTL3MBTL1 | |
| SCHEMBL6292650 | 0.79 | KDM4E (0.37) | KDM4EMAPTCYP1A2CYP2C19 | |
| SCHEMBL6291795 | 0.78 | ALDH1A1 (0.46) | RAB9ASYKNPC1KDM4EMAPT | |
| SCHEMBL6295639 | 0.78 | ADRA1A (0.47) | RAB9ASYKMAPT | |
| SCHEMBL2230732 | 0.73 | KCNA5 (0.51) | KDM4EGAALMNACYP1A2TP53 | |
| SCHEMBL30596267 | 0.73 | KCNA5 (0.51) | KDM4EGAALMNACYP1A2TP53 | |
| SCHEMBL8018549 | 0.72 | CHRM2 (0.42) | RAB9ASYKNPC1KDM4EGAA | |
| SCHEMBL1856673 | 0.72 | SLC6A2 (0.45) | KDM4EMAPTL3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL11398150 | 0.72 | ACHE (0.51) | RAB9ANPC1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846817-B2 | Nicotine receptor ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030027810-A1 | Nicotine receptor ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027810-A1 | Nicotine receptor ligands | CHRNA1, CHRNB1, CHRNA9 | RAB9A 1075/4885SYK 1718/4885NPC1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.